Pancreatic Cancer Pill Doubles Survival

A novel experimental pill has shown remarkable success in doubling the survival time for patients with advanced pancreatic cancer.

The drug, daraxonrasib, targets a mutated protein that fuels tumor growth, offering a significant breakthrough in treating one of the deadliest cancers.

Clinical trials have shown positive results, with some patients living almost twice as long as with standard chemotherapy.

The FDA has permitted expanded access to the drug for eligible patients, marking a crucial step in its development.